

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting

FDA White Oak Campus, Building 31, The Great Room (Rm. 1503)

White Oak Conference Center, Silver Spring, Maryland

October 17, 2012

MEETING ROSTER

DESIGNATED FEDERAL OFFICER (Non-Voting)

Paul T. Tran, RPh

Division of Advisory Committee and Consultant Management

Office of Executive Programs, CDER, FDA

**ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBERS
(Voting)**

Erica H. Brittain, PhD

Mathematical Statistician

Biostatistics Research Branch

National Institute of Allergy and Infectious
Diseases (NIAID)

National Institutes of Health (NIH)

Bethesda, Maryland

Robert J. Smith, MD

Professor of Medicine (Endocrinology)

Alpert Medical School of Brown University

East Providence, Rhode Island

Edward W. Gregg, PhD

Chief, Epidemiology and Statistics Branch

Division of Diabetes Translation

Centers for Disease Control and Prevention (CDC)

Atlanta, Georgia

**ENDOCRINOLOGIC AND METABOLIC DRUGS ADVISORY COMMITTEE MEMBER
(Non-Voting)**

Mads F. Rasmussen, MD, PhD

(Industry Representative)

Executive Director

Diabetes - Clinical Development and Research

Clinical Development, Medical and Regulatory

Affairs Novo Nordisk Inc.

Princeton, New Jersey

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting
October 17, 2012

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Alexander G. Caleb, MD

Associate Professor of Epidemiology & Medicine
Johns Hopkins Bloomberg School of Public Health
Baltimore, Maryland

Hari S. Conjeevaram, MD

Associate Professor of Medicine
Program Director, GI Fellowship Program
Division of Gastroenterology
Medical Director, Student Run Free Clinic
University of Michigan
Ann Arbor, Michigan

David W. Cooke, MD

Associate Professor of Pediatrics
Division of Pediatric Endocrinology
Director, Pediatric Endocrine Fellowship Training
Program
Johns Hopkins University School of Medicine
Baltimore, Maryland

Jacqueline S. Gardner, PhD

Professor Emeritus
School of Pharmacy
University of Washington
Seattle, Washington

David J. Gordon, MD, PhD, MPH

Special Assistant for Clinical Studies
Cardiovascular Clinical Trials
Division of Cardiovascular Sciences
National Heart, Lung, and Blood Institute
(NHLBI), NIH
Bethesda, Maryland

William R. Hiatt, MD, FACP

Professor of Medicine, Division of Cardiology
University of Colorado School of Medicine
President, Colorado Prevention Center (CPC)
Clinical Research
Aurora, Colorado

Joel E. Lavine, MD, PhD

Professor of Pediatrics
Chief, Pediatric Gastroenterology, Hepatology and
Nutrition
Columbia University
New York, New York

David E. Malarkey, DVM, PhD, DACVP

Head, National Toxicology Program Pathology
Group
Cellular and Molecular Pathology Branch
National Institute of Environmental Health
Sciences (NIEHS), NIH
Research Triangle Park, North Carolina

Jeffrey B. Schwimmer, MD

Professor of Pediatrics
Division of Gastroenterology, Hepatology, and
Nutrition
Department of Pediatrics
University of California, San Diego
San Diego, California

Abraham Thomas, MD, MPH, FACP
(Acting Chairperson)

Division Head, Endocrinology, Diabetes, Bone,
and Mineral Disorders
Henry Ford Hospital
Whitehouse Chair of Endocrinology
Detroit, Michigan

FOOD AND DRUG ADMINISTRATION (FDA)

Center for Drug Evaluation and Research (CDER)

Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) Meeting

October 17, 2012

MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Marlena Vega, PhD

(Patient Representative)

New York, New York

Peter W.F. Wilson, MD

Professor of Medicine

Emory University

School of Medicine

Department of Cardiology

Atlanta, Georgia

FDA PARTICIPANTS (Non-Voting)

Christine P. Nguyen, MD

Acting Deputy Director

Office of Drug Evaluation II (ODE-II)

Office of New Drugs (OND), CDER, FDA

Eric C. Colman, MD

Deputy Director

Division of Metabolism and Endocrinology

Products (DMEP), ODE-II, OND, CDER, FDA

James P. Smith, MD, MS

Clinical Reviewer

DMEP, ODE-II, OND, CDER, FDA

Claudia B. Manzo, PharmD

Director

Division of Risk Management (DRISK)

Office of Medication Error Prevention and Risk
Management (OMEPRM)

Office of Surveillance and Epidemiology (OSE)

CDER, FDA